[1]
Negida A, Elfil M, Attia E, et al. Caffeine; the forgotten potential for parkinson’s disease. CNS Neurol Disord Drug Targets 2017; 16(6): 652-7.
[2]
Fatima A, Jyoti S, Siddique YH. Models of Parkinson’s disease with special emphasis on drosophila melanogaster. CNS Neurol Disord Drug Targets 2018; 17(10): 757-66.
[3]
de Farias CC, Maes M, Bonifacio KL, et al. Parkinson’s disease is accompanied by intertwined alterations in iron metabolism and activated immune-inflammatory and oxidative stress pathways. CNS Neurol Disord Drug Targets 2017; 16(4): 484-91.
[5]
Dezsi L, Vecsei L. Monoamine oxidase B inhibitors in Parkinson’s disease. CNS Neurol Disord Drug Targets 2017; 16(4): 425-39.
[7]
Ohno Y, Tokudome K. Therapeutic role of synaptic vesicle glycoprotein 2A (SV2A) in modulating epileptogenesis. CNS Neurol Disord Drug Targets 2017; 16(4): 463-71.
[9]
Mones RJ, Elizan TS, Siegel GJ. Analysis of L-dopa induced dyskinesias
in 51 patients with Parkinsonism. J Neurol Neurosurg
Psychiatry 1971(1); 34(6): 668-73.
[10]
Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson’s disease onset. Mov Disord 2005; 20(3): 342-4.
[11]
Nagatsu T, Sawada M. L-dopa therapy for Parkinson’s disease: Past, present, and future. Parkinsonism Relat Disord 2009; 15: S3-8.
[12]
Schrag A. Entacapone in the treatment of Parkinson’s disease. Lancet Neurol 2005; 4(6): 366-70.
[13]
Chase TN, Oh JD. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 2000; 23: S86-91.
[14]
Klitgaard H. Levetiracetam: The preclinical profile of a new class of antiepileptic drugs? Epilepsia 2008; 42: 13-8.
[15]
Georg MD, Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res 2000; 42(4): 281-5.
[16]
Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002; 136(5): 659-72.
[17]
Hill MP, Brotchie JM, Crossman AR, et al. Levetiracetam interferes with the l-dopa priming process in mptp-lesioned drug-naive marmosets. Clin Neuropharmacol 2004; 27(4): 171-7.
[18]
Bezard E, Hill MP, Crossman AR, et al. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol 2004; 485(1-3): 159-64.
[19]
Hill MP, Bezard E, McGuire SG, et al. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord 2003; 18(11): 1301-5.
[20]
Dyskinesia L, Lyons KE, Pahwa R. Efficacy and tolerability of
levetiracetam in parkinson disease patients with 2006 29(3): 148-
53.
[21]
Wong KK, Alty JE, Goy AG, Raghav S, Reutens DC, Kempster PA. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson’s disease. Mov Disord 2011; 26(8): 1552-5.
[22]
Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: Cochrane book series. Vol. Version 5., Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series 2008.
[23]
Stathis P, Konitsiotis S, Tagaris G, Peterson D. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord 2011; 26(2): 264-70.
[24]
Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: An open label study 2006; 21(8): 2005-7.
[25]
Wolz M, Lohle M, Strecker K, et al. Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. J Neural Transm 2010; 117(11): 1279-86.
[26]
Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA. Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord 2005; 20(9): 1205-9.
[27]
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25(9): 603-5.
[28]
Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: An open label study. Mov Disord 2006; 21(8): 1219-21.
[29]
Francisco S. Levetiracetam in l -dopa-induced dyskinesia. 2005;
28(2): 102-3.
[30]
Deshpande LS, DeLorenzo RJ. Mechanisms of levetiracetam in the control of status epilepticus and epilepsy. Front Neurol 2014; 5: 3389.
[31]
Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004; 101(26): 9861-6.
[32]
Custer KL, Austin NS, Sullivan JM, Bajjalieh SM. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 2006; 26(4): 1303-13.
[33]
Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16(3): 448-58.
[34]
Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-Associated Dyskinesia Risk Among Parkinson Disease Patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006; 63(2): 205.
[35]
Stathis P, Konitsiotis S, Tagaris G, Peterson D. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord 2011; 26(2): 264-70.
[36]
Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: An open label study. Mov Disord 2006; 21(8): 1219-21.
[37]
Wolz M, Löhle M, Strecker K, et al. Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. J Neural Transm 2010; 117(11): 1279-86.
[38]
Busner J, Targum SD. The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry 2007; 4(7): 28-37.
[39]
Hill MP, Bezard E, McGuire SG, et al. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord 2003; 18(11): 1301-5.
[40]
Hill MP, Brotchie JM, Crossman AR, et al. Levetiracetam Interferes with the l-dopa priming process in mptp-lesioned drug-naive marmosets. Clin Neuropharmacol 2004; 27(4): 171-7.
